Odonate Therapeutics announces discontinuation of development of Tesetaxel

Following feedback from the FDA in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company . The Company will work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropriate alternative therapies.